Physician profile
George Salloum
NPI 1003107400
$141,284.21
in general payments reported to CMS, 2019-2025
13 companies · $48K in 2025
The $48K reported for 2025 was more than what 98% of Ophthalmic Plastic and Reconstructive Surgery providers received nationally (typical 2025 total: $299).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $106 · 2020: $98.23 · 2021: $459 · 2022: $2,825 · 2023: $55K · 2024: $35K · 2025: $48K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $69K · Honoraria: $48K · Travel and Lodging: $10K · Food and Beverage: $5,254 · Consulting Fee: $5,100 · Education: $10.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $69,062.50 |
| Honoraria | $48,368.75 |
| Travel and Lodging | $10,001.81 |
| Food and Beverage | $5,253.63 |
| Consulting Fee | $5,100.00 |
| Education | $10.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $82,179.59 | 2024-2025 | Tepezza |
| Horizon Therapeutics Plc | $58,067.75 | 2021-2023 | Tepezza |
| Depuy Synthes Sales INC. | $351.74 | 2020-2022 | |
| Revance Therapeutics, INC. | $181.08 | 2025 | Daxxify |
| Alcon Vision LLC | $147.26 | 2021 | |
| Dompe US, INC. | $93.53 | 2024 | Oxervate |
| Aerie Pharmaceuticals, INC. | $92.36 | 2019 | |
| Merz Pharmaceuticals, LLC | $78.78 | 2023 | Xeomin |
| Biotissue Holdings INC. | $29.49 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $19.78 | 2021 | |
| Galderma Laboratories, L.P. | $17.81 | 2024 | Dysport |
| Merz North America, INC. | $12.84 | 2021 | |
| Medical Device Business Services, INC. | $12.20 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Salloum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.